173 related articles for article (PubMed ID: 31640718)
1. Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Smith AR; Weinstock MT; Siglin AE; Whitby FG; Francis JN; Hill CP; Eckert DM; Root MJ; Kay MS
Retrovirology; 2019 Oct; 16(1):28. PubMed ID: 31640718
[TBL] [Abstract][Full Text] [Related]
2. Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.
Francis JN; Redman JS; Eckert DM; Kay MS
Bioconjug Chem; 2012 Jun; 23(6):1252-8. PubMed ID: 22545664
[TBL] [Abstract][Full Text] [Related]
3. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.
Welch BD; Francis JN; Redman JS; Paul S; Weinstock MT; Reeves JD; Lie YS; Whitby FG; Eckert DM; Hill CP; Root MJ; Kay MS
J Virol; 2010 Nov; 84(21):11235-44. PubMed ID: 20719956
[TBL] [Abstract][Full Text] [Related]
4. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
[TBL] [Abstract][Full Text] [Related]
5. Potent D-peptide inhibitors of HIV-1 entry.
Welch BD; VanDemark AP; Heroux A; Hill CP; Kay MS
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):16828-33. PubMed ID: 17942675
[TBL] [Abstract][Full Text] [Related]
6. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
7. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
8. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
[TBL] [Abstract][Full Text] [Related]
9. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
10. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
11. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.
Balzarini J; François KO; Van Laethem K; Hoorelbeke B; Renders M; Auwerx J; Liekens S; Oki T; Igarashi Y; Schols D
Antimicrob Agents Chemother; 2010 Apr; 54(4):1425-35. PubMed ID: 20047920
[TBL] [Abstract][Full Text] [Related]
12. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
[TBL] [Abstract][Full Text] [Related]
13. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.
Nishimura Y; Francis JN; Donau OK; Jesteadt E; Sadjadpour R; Smith AR; Seaman MS; Welch BD; Martin MA; Kay MS
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22436-22442. PubMed ID: 32820072
[TBL] [Abstract][Full Text] [Related]
16. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
20. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
